Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlenmarkpharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy Glenmark Pharma: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Glenmark Pharma as the stock is on the verge of a breakout to new highs.

    • Bull's Eye: Buy IRB Infra, Glenmark, Crompton, Voltas

      Sharmila Joshi of Peerless Securities advised buying IRB Infrastructure with a target price of Rs 103 and Polaris with a target price of Rs 116.

    • Check out: Short term picks by market experts

      Hemant Thukral of Aditya Birla Money recommends going long on Bata India with a stoploss of Rs 860 and target of Rs 910.

    • Buy Titan & Ultratech; RComm looks expensive: Brokerages

      Here are the four stocks brokerages recommend trading on, namely Titan, Glenmark, Ultratech and Rel Comm.

    • Prefer Glenmark, Aurobindo, Cipla over Ranbaxy: SP Tulsian

      SP Tulsian of sptulsian.com advises to prefer Glenmark Pharma, Aurobindo Pharma or Cipla over Ranbaxy Labs.

    • Citi view: How pharma sector is looking post Q4 debacle

      Prashant Nair of Citi India told CNBC-TV18 that the pharma sector's valuations in current market downturn situation has held up well. He presents his views on buzzing stocks from the sector.

    • Buy Adani Power, Mahindra Satyam, Glenmark Pharma: Tulsian

      SP Tulsian of sptulsian.com is positive on Adani Power, Mahindra Satyam and Glenmark Pharma. He recommends buying these stocks.

    • Bull's Eye: Buy Mahindra Satyam, Voltas; short JSW Energy

      SP Tulsian of sptulsian.com advised buying Adani Power with a target price of Rs 55 and Mahindra Satyam with a target price of Rs 116.

    • Buy Apollo Hospitals Enterprises on dips: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Apollo Hospitals Enterprises on dips. “After the up move Glenmark Pharma went into a small decline and that small decline was a technical flag, which is broken out of the upside and the up move should resume, ”he adds.

    • Sell Aurobindo, Dena Bank, buy Glenmark: Saurabh Mittal

      Saurabh Mittal of Swadeshi Capital recommends selling Aurobindo Pharma with target of Rs 173 and buy Glenmark Pharma with a target of Rs 575.

    • See more upside in Glenmark Pharma: Sukhani

      One can see higher levels in Glenmark Pharma, says Sudarshan Sukhani of s2analytics.com. He advised buying the stock.

    • Bull's Eye: Buy HDIL, Glenmark, Sintex; sell Dena Bank

      SP Tulsian of sptulsian.com advised buying HDIL with a target price of Rs 50 and selling Dena Bank with a target price of Rs 84.

    • Buy Indiabulls Real; sell Glenmark Pharma: SP Tulsian

      SP Tulsian of sptulsian.com advises to buy Indiabulls Real Estate for a price target of Rs 81.

    • Buy Glenmark Pharma, says Sukhani

      One can buy Glenmark Pharma, says Sudarshan Sukhani of s2analytics.com. Its charts are excellent and it is making new highs, he adds.

    • Glenmark Pharma can touch Rs 700: Sukhani

      According to Sudarshan Sukhani of s2analytics.com Glenmark Pharma can touch Rs 700 in the next two years or more.

    • Buy Glenmark, may rise 15%: Rajen Shah

      Rajen Shah of Angel Broking said he would buy Glenmark. According to him, the stock may rise 15 percent.

    • Buy Bata, Glenmark Pharma, Apollo Tyres: Prakash Diwan

      In CNBC-TV18's popular show Bull's Eye, Prakash Diwan of Prakash Diwan's Wealth Circle shares his trading strategies for the day.

    • Bull's Eye: Go long in Bata, Shree Renuka; short UCO Bank

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Hold Glenmark Pharma with a target of Rs 585: Thununguntla

      Jagannadham Thununguntla, Strategist & Head of Research, SMC Global Securities Limited is of the view that one can hold Glenmark Pharma with a target of Rs 585.

    • Buy Glenmark on declines, can touch Rs 600: PN Vijay

      PN Vijay, Portfolio Manager of askpnvijay.com advised buying Glenmark on all declines. He sees the stock touching Rs 600 in the next three-four months.

    • Buy Glenmark Pharma, says Sudarshan Sukhani

      One should buy Glenmark Pharma and hold it for few weeks, says Sudarshan Sukhani of s2analytics.com.

    • Go long in Sintex, Glenmark: Tulsian

      SP Tulsian of sptulsian.com said he would go long in Sintex Industries and Glenmark.

    • Buy Glenmark Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com advises to buy Glenmark Pharma at current levels.

    • Glenmark continues to be a good performer: Thununguntla

      Jagannadham Thununguntla, Strategist & Head of Research, SMC Global Securities Limited is of the view that Glenmark Pharma will continue to be a decent performer.

    • Hold Glenmark Pharma: Sekhar

      Phani Sekhar, Fund Manager, Angel Broking is of the view that one can hold Glenmark Pharma with a target of Rs 600 over the next 12-15 months time frame.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347